Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMA16
- Development stage
- Preclinical
- Lead developer
- University of Missouri-Kansas City
- Modality
- Peptides
01
Overview
CMA16: sourced facts only. name: "We discovered several anti-LAG-3 inhibitor peptides, and the CMA16 peptide showed the highest stability and blocking efficacy." [DOI:10.1158/1538-7445.am2023-lb194]; target: "We discovered several anti-LAG-3 inhibitor peptides, and the CMA16 peptide showed the highest stability and blocking efficacy." [DOI:10.1158/1538-7445.am2023-lb194]; developer: "1University of Missouri- Kansas City, Kansas City, MO." [DOI:10.1158/1538-7445.am2023-lb194]; modality: "We discovered several anti-LAG-3 inhibitor peptides, and the CMA16 peptide showed the highest stability and blocking efficacy." [DOI:10.1158/1538-7445.am2023-lb194]; stage: "CMA16 significantly inhibited the growth of MC38 tumors." [DOI:10.1158/1538-7445.am2023-lb194]
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on CMA16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMA16.